# Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

> **NCT02728050** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 84 (actual)

## Conditions studied

- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia
- de Novo Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Cytarabine
- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Mitoxantrone
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02728050
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2022-02-03
- **Final completion:** 2023-04-04
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728050, "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02728050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*